Aug 3, 2009 - Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
The details can be read here.
No comments:
Post a Comment